Development and in vitro characterization of galactosylated low molecular weight chitosan nanoparticles bearing doxorubicin

AAPS PharmSciTech

Volumn 11, Issue 2, 2010, Pages 686-697

  Jain, Nitin K ^a   Jain, Sanjay K ^a  

^a DR H S GOUR UNIVERSITY   (India)

Author keywords

Doxorubicin; HCC targeting; Low molecular weight chitosan; Nanoparticles

Indexed keywords

ASIALOGLYCOPROTEIN RECEPTOR; CHITOSAN; CYANAMIDE; DOXORUBICIN; LACTOBIONIC ACID; NANOPARTICLE; POLYMER; ANTINEOPLASTIC AGENT; DRUG VEHICLE; EXCIPIENT; GALACTOSE; NANOCAPSULE;

ARTICLE; CELL STRAIN HEPG2; CYTOTOXICITY; DEPOLYMERIZATION; DRUG SCREENING; DRUG TARGETING; GELATION; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CELL; MOLECULAR WEIGHT; PHOTON CORRELATION SPECTROSCOPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SHELLFISH; SUSTAINED DRUG RELEASE; TARGET CELL; TRANSMISSION ELECTRON MICROSCOPY; ANIMAL; CARCINOMA, HEPATOCELLULAR; CELL LINE; CHEMISTRY; DIFFUSION; DRUG FORMULATION; PARTICLE SIZE; PATHOLOGY; PROCEDURES; RAT; SYNTHESIS; TOXICITY; ULTRASTRUCTURE;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CELL LINE; CHITOSAN; DIFFUSION; DOXORUBICIN; DRUG COMPOUNDING; EXCIPIENTS; GALACTOSE; MOLECULAR WEIGHT; NANOCAPSULES; PARTICLE SIZE; RATS; VEHICLES; PHARMACEUTICAL VEHICLES;

EID: 77954816831     PISSN: None     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/s12249-010-9422-z     Document Type: Article

References (49)

1. Ann P. Looking at liver cancer. Nursing. 2006;36:52-5.
2. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol. 2001;35:421-30.
3. Liu J, Williams RO. Long-term stability of heat-humidity cured cellulose acetate phthalate coated beads. Eur J Pharm Biopharm. 2002;53:167-73. (Pubitemid 34189790)
4. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology. 2003;37:429-42.
5. Baird RD, Kaye SB. Drug resistance reversal-are we getting closer? Eur J Cancer. 2003;39:2450-61.
6. Molema G, Meijer D K F. Targeting of drugs to various blood cell types using (neo-) glycoproteins, antibodies and other protein carriers. Adv Drug Deliv Rev. 1994;14:25-50.
7. Meijer D K F, Jansen RW, Molema G. Drug targeting systems for antiviral agents: options and limitations. Antivir Res. 1992;18:215-58.
8. Gu FX, Karnik R, Wang AZ, Alexis F, Levy-Nissenbaum E, Hong S et al. Targeted nanoparticles for cancer therapy. Nanotoday. 2007;2:14-21.
9. Muggia FM, Hainsworth JD, Jeffers S. Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol. 1997;15:987-93.
10. Cuvier C, Roblot-Treupel L, Millot JM, Lizard G, Chevillard S, Manfait M et al. Doxorubicin-loaded nanospheres bypass tumor cell multidrug resistance. Biochem Pharmacol. 1992;44:509-17.
11. De Colin V A C, Dubernet C, Nemati F, Soma E, Appel M, Ferte J et al. Reversion of multidrug resistance with polyalkylcyanoacrylate nanoparticles: towards a mechanism of action. Br J Cancer. 1997;76:198-205.
12. Bennis S, Chapey C, Robert J, Couvreur P. Enhanced cytotoxicity of doxorubicin encapsulated in polyisohexylcyanoacrylate nanospheres against multidrug-resistant tumour cells in culture. Eur J Cancer. 1994;30:89-93.
13. Ashwell G, Morell AG. The role of surface carbohydrates in the hepatic recognition and transport of circulating glycoproteins. Adv Enzymol Relat Areas Mol Biol. 1974;41:99-128.
14. Sarasam AR, Krishnaswamy RK, Madihally SV. Blending chitosan with polycaprolactone: effects on physicochemical and antibacterial properties. Biomacromolecules. 2006;7:1131-8.
15. Nicol S. Life after death for empty shells. New Sci. 1991;129:46-8.
16. Tharanathan RN, Prashanth KVS 2001. Indian patent, 433/DEL/01.
17. Kubota N, Tatsumoto N, Sano T, Toya K. Simple preparation of half N-acetylated chitosan highly soluble in water and aqueous organic solvents. Carbohydr Res. 2000;324:268-74.
18. Xu J, McCarthy SP, Fross RA, Kaplan DL. Chitosan film acylation and effects on biodegradability. Macromolecules. 1996;29:3436-40.
19. Pantaleone D, Yalpani M, Scollar M. Preparation of methyl 2, 3-di-O-mesyl-4, 6-thioanhydro-alpha-D-galactopyranoside and methyl 2-O-mesyl-4, 6-thioanhydro-alpha-D-gulopyranoside. Carbohydr Res. 1992;237:325-32.
20. Wang W, Bo S, Li S, Qin W. Determination of the Mark-Houwink equation for chitosans with different degrees of deacetylation. Int J Biol Macromol. 1991;13:281-5.
21. Gao S, Chen J, Xu X, Zhi D, Yang Y, Hua Z et al. Galactosylated low molecular weight chitosan as DNA carrier for hepatocytetargeting. Int J Pharm. 2003;255:57-68.
22. Vila A, Sanchez A, Janes K, Behrens I, Kissel T, Vila JL et al. Low molecular weight chitosan nanoparticles as new carriers for nasal vaccine delivery in mice. Eur J Pharm Biopharm. 2004;57:123-31.
23. Truter EJ, Santos AS, Els WJ. Assessment of the antitumour activity of targeted immunospecific albumin microspheres loaded with cisplatin and 5-fluorouracil: toxicity against a rodent ovarian carcinoma in vitro. Cell Biol Int. 2001;25:51-9.
24. Janes KA, Fresneau MP, Marazuela A, Fabra A, Alonso MJ. Chitosan nanoparticles as delivery systems for doxorubicin. J Control Release. 2001;73:255-67.
25. Yoshida M, Yamamoto N, Uehara T, Terao R, Nitta T, Harada N et al. Kupffer cell targeting by intraportal injection of the HVJ cationic liposome. Eur Surg Res. 2002;34:251-9.
26. Braet F, Wisse E. Structural and functional aspects of liver sinusoidal endothelial cell fenestrae: a review. Comp Hepatol. 2002;1:1-17.
27. Kim TH, Jiang HL, Nah JW, Cho MH, Akaike T, Cho CS. Receptor-mediated gene delivery using chemically modified chitosan. Biomed Mater. 2007;2: S95-100. (Pubitemid 47354097)
28. Kwoh DY, Coffin CC, Lollo CP, Jovenal J, Banaszczyk MG, Mullen P, et al. (1999) Stabilization of poly-L-lysine/DNA polyplexes for in vivo gene delivery to the liver. Biochim Biophys Acta: Gene Structure and Expression 1444:171-190.
29. Agnihotri SA, Mallikarjuna NN, Aminabhavi TM. Recent advances on chitosan-based micro-and nanoparticles in drug delivery. J Control Release. 2004;100:5-28.
30. Hsu SC, Don TM, Chiua WY. Free radical degradation of chitosan with potassium persulfate. Polym Degrad Stab. 2002;75:73-83.
31. Huang M, Khor E, Lim L. Uptake and cytotoxicity of chitosan molecules and nanoparticles: effects of molecular weight and degree of deacetylation. Pharm Res. 2004;21:344-53.
32. Mao S, Shuai X, Unger F. The depolymerization of chitosan: effects on physicochemical and biological properties. Int J Pharm. 2004;281:45-54.
33. Park IK, Kim TH, Park YH, Shin BA, Choi ES, Chowdhury EH et al. Galactosylated chitosan-graft-poly (ethylene glycol) as hepatocytetargeting DNA carrier. J Control Release. 2001;76:349-62.
34. Ghosh SS, Kao PM, McCue AW, Chappelle HL. Use of maleimide-thiol coupling chemistry for efficient synthesis of digonucleotide-enzyme conjugate hybridisation probes. Bioconjug Chem. 1990;1:71-6.
35. Kumbar SG, Kulkarni AR, Aminabhavi TM. Crosslinked chitosan microspheres for encapsulation of diclofenac sodium: effect of crosslinking agent. J Microencapsulation. 2002;19:173-80.
36. Mao HQ, Roy K, Troung-Le VL, Janes KA, Lim KY, Wang Y et al. Chitosan-DNA nanoparticles as gene carriers: synthesis, characterization and transfection efficiency. J Control Release. 2001;70:399-421.
37. He P, Davis SS, Illum L. Chitosan microspheres prepared by spray drying. Int J Pharm. 1999;187:53-65.
38. Mitra S, Gaur U, Ghosh PC, Maitra AN. Tumour targeted delivery of encapsulated dextran-doxorubicin conjugate using chitosan nanoparticles as carrier. J Control Release. 2001;74:317-23.
39. Tokumitsu H, Ichikawa H, Fukumori Y. Chitosan-gadopentetic acid complex nanoparticles for gadolinium neutron-capture therapy of cancer: preparation by novel emulsion-droplet coalescence technique and characterization. Pharm Res. 1999;16:1830-5. (Pubitemid 30040698)
40. Shu XZ, Zhu KJ. Controlled drug release properties of ionically cross-linked chitosan beads: the influence of anion structure. Int J Pharm. 2002;233:217-25.
41. Xu Y, Du Y. Effect of molecular structure of chitosan on protein delivery properties of chitosan nanoparticles. Int J Pharm. 2003;250:215-26.
42. Berth G, Dautzenberg H, Peter MG. Physico-chemical characterization of chitosans varying in degree of acetylation. Carbohydr Polym. 1998;36:205-16.
43. Aiba SI. Studies on chitosan: 3. Evidence for the presence of random and block copolymer structures in partially N-acetylated chitosans. Int J Bio Macromol. 1991;13:40-4.
44. Pedroni VI, Schulz PC, Gashaider ME, Andreucetti N. Chitosan structure in aqueous solution. Colloid Polym Sci. 2003;282:100-2.
45. Gan Q, Wang T, Cochrane C, McCarron P. Modulation of surface charge, particle size and morphological properties of chitosan-TPP nanoparticles intended for gene delivery. Colloids Surf B Biointerfaces. 2005;44:65-73.
46. Qi LF, Xu ZR, Li Y, Jiang X, Han XY. In vitro effects of chitosan nanoparticles on proliferation of human gastric carcinoma cell line MGC803 cells. World J Gastroenterol. 2005;11:5136-41.
47. Fernandez-Urrusuno R, Calvo P, Remunan-Lopez C, Vila JL, Alonso MJ. Enhancement of nasal absorption of insulin using chitosan nanoparticles. Pharm Res. 1999;16:1576-81.
48. Zhou SB, Deng XM, Li XH. Investigation on a novel corecoated microspheres protein delivery system. J Control Release. 2001;75:27-36.
49. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983;65:55-63.